Biomedical Engineering (BME) 3 Practice Test

Understanding U.S. medical device regulation hinges on risk-based pathways. The main idea here is the difference between PMA and 510(k). PMA, or Pre-Market Approval, is required for high-risk devices and demands solid evidence of safety and effectiveness, typically including clinical data. This means the FDA must be convinced the device works as claimed and does not pose undue risk before it can be marketed. The 510(k) process, on the other hand, is a substantial equivalence route: a device can enter the market if it is shown to be substantially equivalent to a legally marketed predicate device with the same intended use and similar technological characteristics, often with less new clinical data. This path is commonly used for moderate-risk devices and some lower-risk ones. So the key distinction is whether new clinical proof of benefit is required (PMA) versus proving similarity to an existing device (510(k)). The other statements aren’t correct because PMA is not just marketing authorization, 510(k) isn’t for high-risk devices, and they are not the same pathway.